Rigel Pharmaceuticals

🇮🇳India

Country: 🇮🇳India

Ownership: -

Employees: 147

Market Cap: -

Website

Introduction: Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. The company's products include Tavalisse, Fostamatinib and R835. Rigel Pharmaceuticals was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.

Clinical Trials

Open Label Study of R788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)

Phase 3

Completed

Conditions: Immune Thrombocytopenic Purpura

Interventions: Drug: Fostamatinib Disodium

First Posted Date: 2014-03-04

Last Posted Date: 2023-12-11

Lead Sponsor: Rigel Pharmaceuticals

Target Recruit Count: 123

Registration Number: NCT02077192

Locations: 🇳🇱
HAGA ziekenhuis, Den Haag, NL, Netherlands
🇧🇬
UMHAT Aleksandrovska, EAD, Sofia, Bulgaria
🇺🇸
East Carolina University, Brody School of Medicine, Greenville, North Carolina, United States

and more 52 locations

A Efficacy and Safety Study of R935788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)

Phase 3

Completed

Conditions: Immune Thrombocytopenic Purpura

Interventions: Drug: Fostamatinib disodium
Drug: Placebo

First Posted Date: 2014-03-03

Last Posted Date: 2019-02-12

Lead Sponsor: Rigel Pharmaceuticals

Target Recruit Count: 76

Registration Number: NCT02076399

Locations: 🇺🇸
University of Southern California, Los Angeles, California, United States
🇬🇧
Colchester General Hospital, Colchester, Essex, United Kingdom
🇮🇹
OspedaleCivile-ClinicaEmatologica/PUGD, Udine, Italy

and more 49 locations

A Efficacy and Safety Study of Fostamatinib in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)

Phase 3

Completed

Conditions: Immune Thrombocytopenic Purpura

Interventions: Drug: Fostamatinib Disodium
Drug: Placebo

First Posted Date: 2014-03-03

Last Posted Date: 2019-01-25

Lead Sponsor: Rigel Pharmaceuticals

Target Recruit Count: 74

Registration Number: NCT02076412

Locations: 🇳🇴
Haukeland University Hospital, Bergen, Norway
🇦🇹
Medizinische Universitaet Wien / AKH Wien, Wien, AU, Austria
🇷🇴
Spitalul Clinic Coltea, Hematologie, Bucuresti, Romania

and more 32 locations

Safety and Efficacy Study of R932348 Ophthalmic Solution in Chronic Ocular Graft Versus Host Disease Patients(DROPS-2)

Phase 2

Completed

Conditions: Chronic Graft-versus-host Disease

Interventions: Drug: R348 Ophthalmic Solution, 0.2%
Drug: R348 Ophthalmic Solution, 0.5%
Other: Placebo Ophthalmic Solution

First Posted Date: 2014-01-20

Last Posted Date: 2016-10-10

Lead Sponsor: Rigel Pharmaceuticals

Target Recruit Count: 35

Registration Number: NCT02040623

Locations: 🇺🇸
U. Miami - Bascom Palmer Eye Institute, Plantation, Florida, United States
🇺🇸
Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, United States

To Assess the Safety and Efficacy of R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca

Phase 2

Completed

Conditions: Keratoconjunctivitis Sicca

Interventions: Drug: R348 Ophthalmic Solution, 0.5%
Drug: Placebo
Drug: R348 Ophthalmic Solution, 0.2%

First Posted Date: 2013-07-16

Last Posted Date: 2016-10-03

Lead Sponsor: Rigel Pharmaceuticals

Target Recruit Count: 204

Registration Number: NCT01900249

Locations: 🇺🇸
Chicago Research Center, Chicago, Illinois, United States
🇺🇸
Chattanooga Eye Institute, Chattanooga, Tennessee, United States
🇺🇸
Eye Clinics of South Texas, San Antonio, Texas, United States

and more 17 locations

A Safety, Tolerability and Pharmacokinetics Study of R932348 Eye Drops in Patients With Dry Eye Disease

Phase 1

Completed

Conditions: Keratoconjunctivitis Sicca

Interventions: Drug: R348 Ophthalmic Solution, 0.5%
Drug: R348 Ophthalmic Solution, 1.0%
Drug: R348 Ophthalmic Solution, 0.2%
Drug: Placebo

First Posted Date: 2012-11-27

Last Posted Date: 2014-08-04

Lead Sponsor: Rigel Pharmaceuticals

Target Recruit Count: 36

Registration Number: NCT01733992

Locations: 🇺🇸
Andover Eye Associates, Andover, Massachusetts, United States

Safety and Efficacy of Topical R333 in Patients With Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE) Lesions

Phase 2

Completed

Conditions: Lupus Erythematosus, Discoid
Lupus Erythematosus, Systemic

Interventions: Drug: Placebo
Drug: R932333

First Posted Date: 2012-05-11

Last Posted Date: 2016-07-14

Lead Sponsor: Rigel Pharmaceuticals

Target Recruit Count: 54

Registration Number: NCT01597050

Locations: 🇺🇸
Wallace Rheumatic Study Center, Los Angeles, California, United States
🇨🇦
Lynderm Research, Inc, Markham, Ontario, Canada
🇺🇸
Stanford Dermatology, Redwood City, California, United States

and more 12 locations

A Safety and Efficacy Study of Inhaled R940343 in Patients With Mild to Moderate Asthma

Phase 2

Completed

Conditions: Asthma

Interventions: Drug: R940343 1mg
Drug: R940343 2mg
Drug: Placebo

First Posted Date: 2012-05-03

Last Posted Date: 2016-09-29

Lead Sponsor: Rigel Pharmaceuticals

Target Recruit Count: 301

Registration Number: NCT01591044

Locations: 🇺🇸
Allergy Consultants, PA, Verona, New Jersey, United States
🇺🇸
The Asthma & Allergy Center, Bellevue, Nebraska, United States
🇺🇸
National Allergy, Asthma and Uticaria Center of Charleston, Charleston, South Carolina, United States

and more 56 locations